Ad
related to: bronchogenic carcinoma treatment cost- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Lung Cancer Treatment
Free Lung Cancer Treatment Guide.
Find Lung Cancer Treatment Options.
- Lung Cancer Signs
Free Lung Cancer Treatment Guide.
Lung Cancer Signs and Symptoms.
- Lung Cancer Screening
Learn About Lung Cancer Screening.
Is This the Right Test for You?
- Need a Second Opinion?
Search results
Results from the WOW.Com Content Network
Lung cancer, also known as lung carcinoma, is a malignant tumor that begins in the lung. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals. Damaged airway cells gain the ability to multiply unchecked, causing the growth of a tumor.
This study was a retrospective, case-control study that compared smoking habits of 684 individuals with bronchogenic carcinoma to those without the condition. [12] The survey included questions about smoking: starting age, 20 year tobacco consumption, brands used; as well as inquires about exposure to hazardous agents in the workplace, alcohol use, and causes of death for family members.
The Pancoast tumor was first described by Hare in 1838 as a "tumor involving certain nerves". [2] It was not until 1924 that the tumor was described in further detail, when Henry Pancoast, a radiologist from Philadelphia, published an article in which he reported and studied many cases of apical chest tumors that all shared the same radiographic findings and associated clinical symptoms, such ...
Immunotherapy is a type of cancer treatment that activates the immune system to fight cancer. Nivolumab is a fully human IgG4 antibody targeting programmed death receptor 1 (PD-1). In 2015, nivolumab was approved for the treatment of people with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based ...
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. [1] [2] [3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma.
Small-cell lung carcinoma (SCLC) has long been divided into two clinicopathological stages, termed limited stage (LS) and extensive stage (ES). [8] The stage is generally determined by the presence or absence of metastases, whether or not the tumor appears limited to the thorax, and whether or not the entire tumor burden within the chest can feasibly be encompassed within a single radiotherapy ...
The incidence of bronchiolo-alveolar carcinoma has been reported to vary from 4–24% of all lung cancer patients. [23] An analysis of Surveillance epidemiology and End results registry ( SEER) by Read et al. revealed that although the incidence of BAC has increased over the past two decade it still constitutes less than 4% of NSCLC in every ...
Compared to most other lung cancer variants, cells comprising GCCL tend to be much larger (up to 150 micrometers diameter, or even larger), [9] Both cells and nuclei show extreme variation in size distribution and shape. Carcinomatous giant cells carcinoma nuclei have been reported to average 5 times the size of lymphocyte nuclei. [8]
Ad
related to: bronchogenic carcinoma treatment cost